|
US949A
(en)
|
|
1838-09-27 |
|
Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton |
|
US510A
(en)
|
|
1837-12-07 |
|
soeel |
|
US5861A
(en)
|
|
1848-10-17 |
|
Locking umbrella and parasol |
|
US5863A
(en)
|
|
1848-10-17 |
|
Matthias p |
|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
|
GB1051218A
(cg-RX-API-DMAC7.html)
|
1963-03-09 |
|
|
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
US5034393A
(en)
|
1989-07-27 |
1991-07-23 |
Dowelanco |
Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
|
|
US5852029A
(en)
|
1990-04-10 |
1998-12-22 |
Israel Institute For Biological Research |
Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
|
|
US5407938A
(en)
|
1990-04-10 |
1995-04-18 |
Israel Institute For Biological Research |
Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
|
|
US5534520A
(en)
|
1990-04-10 |
1996-07-09 |
Fisher; Abraham |
Spiro compounds containing five-membered rings
|
|
WO1993017681A1
(en)
|
1992-03-02 |
1993-09-16 |
Abbott Laboratories |
Angiotensin ii receptor antagonists
|
|
WO1993017682A1
(en)
|
1992-03-04 |
1993-09-16 |
Abbott Laboratories |
Angiotensin ii receptor antagonists
|
|
EP0583861A1
(en)
|
1992-08-14 |
1994-02-23 |
Pioneer Electronic Corporation |
Organic electroluminescene device
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
TW414798B
(en)
|
1994-09-07 |
2000-12-11 |
Thomae Gmbh Dr K |
Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
CA2223081C
(en)
|
1995-06-07 |
2001-03-06 |
Pfizer Inc. |
Heterocyclic ring-fused pyrimidine derivatives
|
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
|
US6395733B1
(en)
|
1995-06-07 |
2002-05-28 |
Pfizer Inc |
Heterocyclic ring-fused pyrimidine derivatives
|
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
|
DK0780386T3
(da)
|
1995-12-20 |
2003-02-03 |
Hoffmann La Roche |
Matrixmetalloproteaseinhibitorer
|
|
ZA9756B
(en)
|
1996-01-16 |
1997-07-17 |
Warner Lambert Co |
Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
|
|
DE19608653A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
JP3195756B2
(ja)
|
1996-07-04 |
2001-08-06 |
公子 吉水 |
潤滑補助体
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
AR007855A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
|
|
EP0923585B1
(en)
|
1996-07-18 |
2002-05-08 |
Pfizer Inc. |
Phosphinate based inhibitors of matrix metalloproteases
|
|
EP0922030A1
(en)
|
1996-08-23 |
1999-06-16 |
Pfizer Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
|
IL129825A0
(en)
|
1996-11-27 |
2000-02-29 |
Pfizer |
Fused bicyclic pyrimidine derivatives
|
|
ZA9711102B
(en)
|
1996-12-16 |
1998-08-13 |
Yamanouchi Pharma Co Ltd |
N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative
|
|
US6077864A
(en)
|
1997-01-06 |
2000-06-20 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
|
HUP0000852A2
(hu)
|
1997-02-03 |
2001-05-28 |
Pfizer Products Inc. |
Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
|
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
NZ336836A
(en)
|
1997-02-11 |
2001-02-23 |
Pfizer |
Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
|
|
DE69818675T2
(de)
|
1997-07-29 |
2004-07-29 |
Alcon Laboratories, Inc., Fort Worth |
Galaktomannanpolymere und borat enthaltende augenarzneimittel
|
|
TR200000368T2
(tr)
|
1997-08-08 |
2000-07-21 |
Pfizer Products Inc. |
Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
US6708022B1
(en)
|
1997-12-22 |
2004-03-16 |
Renesas Technology Corporation |
Power amplification system and mobile radio communication terminal
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
|
JP4462654B2
(ja)
|
1998-03-26 |
2010-05-12 |
ソニー株式会社 |
映像素材選択装置及び映像素材選択方法
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
EP1004578B1
(en)
|
1998-11-05 |
2004-02-25 |
Pfizer Products Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
|
JP2002532415A
(ja)
|
1998-12-16 |
2002-10-02 |
ワーナー−ランバート・カンパニー |
Mek阻害剤による関節炎の治療
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
DE19911510A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
GB9906566D0
(en)
|
1999-03-23 |
1999-05-19 |
Zeneca Ltd |
Chemical compounds
|
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
|
EP1081137A1
(en)
|
1999-08-12 |
2001-03-07 |
Pfizer Products Inc. |
Selective inhibitors of aggrecanase in osteoarthritis treatment
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
IL139197A0
(en)
|
1999-10-29 |
2001-11-25 |
Pfizer Prod Inc |
Use of corticotropin releasing factor antagonists and related compositions
|
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
EP1149583A3
(en)
|
2000-04-13 |
2001-11-14 |
Pfizer Products Inc. |
Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
|
|
AU7349801A
(en)
|
2000-07-19 |
2002-01-30 |
Warner Lambert Co |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
US20030207878A1
(en)
|
2000-08-09 |
2003-11-06 |
Hennequin Lawrent Francois Andre |
Chemical compounds
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7141576B2
(en)
|
2001-01-16 |
2006-11-28 |
Smithkline Beecham (Cork) Limited |
Cancer treatment method
|
|
DE10115921A1
(de)
|
2001-03-30 |
2002-10-02 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen
|
|
ES2263743T3
(es)
|
2001-04-13 |
2006-12-16 |
Pfizer Products Inc. |
Derivados de 4-aminopiridopirimidina sustituidos con un grupo biciclico.
|
|
EP1434579B1
(en)
|
2001-10-09 |
2011-06-08 |
Amgen Inc. |
Imidazole derivatives as antiinflammatory agents
|
|
EP1465900B1
(en)
|
2002-01-10 |
2008-05-14 |
Bayer HealthCare AG |
Rho-kinase inhibitors
|
|
EP1478648B1
(en)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorus-containing compounds and uses thereof
|
|
CA2478065C
(en)
|
2002-03-08 |
2013-01-08 |
Eisai Co. Ltd. |
Macrocyclic compounds useful as pharmaceuticals
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
AU2003229305A1
(en)
|
2002-05-17 |
2003-12-02 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
WO2004010929A2
(en)
|
2002-07-25 |
2004-02-05 |
Scios, Inc. |
METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
|
|
US20040146509A1
(en)
|
2002-07-25 |
2004-07-29 |
Zhihe Li |
Methods for improvement of lung function using TGF-beta inhibitors
|
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
WO2004060400A1
(ja)
|
2003-01-06 |
2004-07-22 |
Mitsubishi Pharma Corp |
上皮成長因子受容体を分子標的とする抗精神病薬
|
|
US8748601B2
(en)
|
2003-04-11 |
2014-06-10 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
|
EP1636195A1
(en)
|
2003-05-27 |
2006-03-22 |
Pfizer Products Inc. |
Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
EP1654002B2
(en)
|
2003-08-07 |
2014-01-29 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
AU2004293026B2
(en)
|
2003-11-21 |
2012-01-19 |
Array Biopharma Inc. |
AKT protein kinase inhibitors
|
|
TW200538120A
(en)
|
2004-02-20 |
2005-12-01 |
Kirin Brewery |
Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
|
|
MXPA06013250A
(es)
|
2004-05-14 |
2007-02-28 |
Abbott Lab |
Inhibidores de quinasa como agentes terapeuticos.
|
|
US20090155247A1
(en)
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
|
US20060188498A1
(en)
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
GB0510139D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B1
|
|
KR101139038B1
(ko)
|
2005-06-28 |
2012-05-02 |
삼성전자주식회사 |
피리미도피리미딘 유도체 및 이를 이용한 유기 박막 트랜지스터
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
MX2008002114A
(es)
|
2005-07-21 |
2008-04-17 |
Ardea Biosciences Inc |
Inhibidores de n-(arilamino)-sulfonamida de mek.
|
|
WO2007035428A1
(en)
|
2005-09-15 |
2007-03-29 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
|
US7547782B2
(en)
|
2005-09-30 |
2009-06-16 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
|
DE602006021645D1
(de)
|
2005-11-15 |
2011-06-09 |
Array Biopharma Inc |
Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
|
|
TW200730527A
(en)
|
2005-12-02 |
2007-08-16 |
Takeda Pharmaceuticals Co |
Fused heterocyclic compound
|
|
WO2007081517A2
(en)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Anti-viral compounds
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US20100234351A1
(en)
|
2006-02-23 |
2010-09-16 |
Takeda Pharmaceutical Company Limited |
Fused nitrogen-comprising heterocyclic compound
|
|
US7351434B2
(en)
|
2006-04-07 |
2008-04-01 |
Academia Sinica |
Therapeutic Gastrodia extracts
|
|
US8129357B2
(en)
|
2006-04-07 |
2012-03-06 |
Academia Sinica |
Method of making and using an adenosine analogue
|
|
EP2094276A4
(en)
|
2006-12-20 |
2011-01-05 |
Abbott Lab |
ANTIVIRAL COMPOUNDS
|
|
US20090004185A1
(en)
|
2007-01-11 |
2009-01-01 |
Wyeth |
Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
|
|
ES2470341T3
(es)
|
2007-04-05 |
2014-06-23 |
Amgen, Inc |
Moduladores de la aurora cinasa y método de uso
|
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US8633186B2
(en)
|
2007-06-08 |
2014-01-21 |
Senomyx Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
JP2009046453A
(ja)
|
2007-08-22 |
2009-03-05 |
Takeda Chem Ind Ltd |
縮合複素環化合物
|
|
BRPI0816769A2
(pt)
|
2007-09-12 |
2016-11-29 |
Hoffmann La Roche |
combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP5600063B2
(ja)
|
2007-10-19 |
2014-10-01 |
セルジーン アビロミクス リサーチ, インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
WO2009055730A1
(en)
|
2007-10-25 |
2009-04-30 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
US7829574B2
(en)
|
2008-05-09 |
2010-11-09 |
Hutchison Medipharma Enterprises Limited |
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
|
|
CN101575333B
(zh)
|
2008-05-09 |
2011-06-22 |
和记黄埔医药(上海)有限公司 |
一种喹唑啉衍生物及其医药用途
|
|
WO2009140549A1
(en)
|
2008-05-14 |
2009-11-19 |
Amgen Inc. |
Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
TW201014860A
(en)
|
2008-09-08 |
2010-04-16 |
Boehringer Ingelheim Int |
New chemical compounds
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
WO2010042489A2
(en)
|
2008-10-06 |
2010-04-15 |
Emory University |
Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
|
|
AU2009303602B2
(en)
|
2008-10-14 |
2012-06-14 |
Sunshine Lake Pharma Co., Ltd. |
Compounds and methods of use
|
|
CA2742007C
(en)
|
2008-10-29 |
2014-07-08 |
Deciphera Pharmaceuticals, Llc |
Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
CN102264737A
(zh)
|
2008-12-23 |
2011-11-30 |
雅培制药有限公司 |
抗病毒化合物
|
|
CN101759683B
(zh)
|
2008-12-25 |
2011-12-28 |
哈尔滨誉衡药业股份有限公司 |
二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
|
|
EP2398797B1
(en)
|
2009-02-17 |
2013-11-06 |
Boehringer Ingelheim International GmbH |
Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
CN102086211B
(zh)
|
2009-12-08 |
2013-09-11 |
广东东阳光药业有限公司 |
作为蛋白激酶抑制剂的芳杂环化合物
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
WO2011146401A1
(en)
|
2010-05-17 |
2011-11-24 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
|
CN103079644B
(zh)
|
2010-06-11 |
2017-02-15 |
协和发酵麒麟株式会社 |
抗tim‑3抗体
|
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
|
ES2526124T3
(es)
|
2010-06-16 |
2015-01-07 |
Cymabay Therapeutics, Inc. |
Agonistas del receptor GPR120 y sus usos
|
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
SG187064A1
(en)
|
2010-07-14 |
2013-02-28 |
Zhejiang Beta Pharma Inc |
NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
|
|
CN102558147B
(zh)
|
2010-12-23 |
2014-09-17 |
江苏先声药物研究有限公司 |
化合物、制备方法及应用
|
|
US20130023531A1
(en)
|
2011-01-27 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
|
|
WO2012125668A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
US8686119B2
(en)
|
2011-07-24 |
2014-04-01 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
|
WO2013033981A1
(zh)
|
2011-09-06 |
2013-03-14 |
江苏先声药物研究有限公司 |
一类2,7-萘啶衍生物及其制备方法和应用
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
CN102516232A
(zh)
*
|
2011-12-14 |
2012-06-27 |
无锡美克赛医药科技有限公司 |
一种ErbB2的小分子选择性抑制剂及其应用
|
|
TW201336847A
(zh)
|
2012-02-07 |
2013-09-16 |
Taiho Pharmaceutical Co Ltd |
喹啉基吡咯并嘧啶化合物或其鹽
|
|
JP6003976B2
(ja)
|
2012-02-22 |
2016-10-05 |
コニカミノルタ株式会社 |
光学フィルム、円偏光板および画像表示装置
|
|
US8889666B2
(en)
|
2012-02-23 |
2014-11-18 |
Taiho Pharmaceutical Co., Ltd. |
Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof
|
|
US9175082B2
(en)
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
RS60538B1
(sr)
|
2013-03-15 |
2020-08-31 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 vezujući proteini
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
US20140336182A1
(en)
|
2013-05-13 |
2014-11-13 |
Amgen Inc. |
Aurora Kinase Modulators and Method of Use
|
|
CA3175360C
(en)
|
2013-05-31 |
2024-05-28 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
TWI603971B
(zh)
|
2013-08-22 |
2017-11-01 |
Taiho Pharmaceutical Co Ltd |
Novel quinoline substituted compounds
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
|
WO2015085238A1
(en)
|
2013-12-05 |
2015-06-11 |
The Regents Of The University Of California, A California Corporation |
Inhibitors of lpxc
|
|
US9815797B2
(en)
|
2013-12-09 |
2017-11-14 |
Ucb Biopharma Sprl |
Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
LT3094351T
(lt)
|
2014-01-15 |
2022-04-11 |
Kadmon Corporation, Llc |
Imunitetą moduliuojantys agentai
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
WO2015116539A1
(en)
|
2014-01-28 |
2015-08-06 |
Bristol-Myers Squibb Company |
Anti-lag-3 antibodies to treat hematological malignancies
|
|
SG11201603960XA
(en)
|
2014-01-31 |
2016-07-28 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-drug conjugate
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
CA2943231C
(en)
|
2014-03-20 |
2023-10-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
US20170166598A1
(en)
|
2014-05-13 |
2017-06-15 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
|
US9885721B2
(en)
|
2014-05-29 |
2018-02-06 |
Spring Bioscience Corporation |
PD-L1 antibodies and uses thereof
|
|
CA2949793C
(en)
|
2014-06-19 |
2024-02-27 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
MY193661A
(en)
|
2014-11-06 |
2022-10-24 |
Hoffmann La Roche |
Anti-tim3 antibodies and methods of use
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
US10435402B2
(en)
|
2015-01-08 |
2019-10-08 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
WO2016128908A1
(en)
|
2015-02-12 |
2016-08-18 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
AU2016229189A1
(en)
|
2015-03-06 |
2017-09-21 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind TIM3
|
|
PL3277321T3
(pl)
|
2015-04-01 |
2024-11-18 |
Anaptysbio, Inc. |
Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
|
|
GB201505658D0
(en)
|
2015-04-01 |
2015-05-13 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
CN104876912B
(zh)
|
2015-04-08 |
2017-07-21 |
苏州云轩医药科技有限公司 |
Wnt信号通路抑制剂及其应用
|
|
US20210323976A1
(en)
|
2015-05-13 |
2021-10-21 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
|
WO2016191471A1
(en)
|
2015-05-27 |
2016-12-01 |
Metastat, Inc. |
Method of use for inhibitors of epidermal growth factor receptor variants ii, iii and vi
|
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
|
HUE054985T2
(hu)
|
2015-10-09 |
2021-11-29 |
Boehringer Ingelheim Int |
Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok
|
|
CN108697699A
(zh)
|
2015-10-23 |
2018-10-23 |
苏尼西斯制药有限公司 |
用于治疗癌症的杂环pdk1抑制剂
|
|
CA3009474A1
(en)
|
2015-12-22 |
2017-06-29 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
JP6842474B2
(ja)
|
2016-02-02 |
2021-03-17 |
深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. |
ステロイド系化合物、当該化合物を含む組成物及びその使用
|
|
CN115057861A
(zh)
|
2016-03-01 |
2022-09-16 |
上海医药集团股份有限公司 |
一种含氮杂环化合物、制备方法、中间体、组合物和应用
|
|
EP3464267B1
(en)
|
2016-05-23 |
2020-09-23 |
Boehringer Ingelheim International GmbH |
New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors
|
|
AU2017350440B2
(en)
|
2016-10-31 |
2023-01-12 |
Taiho Pharmaceutical Co., Ltd. |
Selective inhibitor of exon 20 insertion mutant EGFR
|
|
CN108101905A
(zh)
|
2016-11-24 |
2018-06-01 |
中国科学院上海药物研究所 |
嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
|
|
EP3558979B1
(en)
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
US20180303821A1
(en)
|
2017-04-24 |
2018-10-25 |
BraneQuest, Inc. |
Membrane active molecules
|
|
FR3066761B1
(fr)
|
2017-05-23 |
2020-10-30 |
Centre Nat Rech Scient |
Nouveaux composes inhibiteurs des canaux ioniques
|
|
CN109020957B
(zh)
|
2017-06-12 |
2023-01-13 |
南京天印健华医药科技有限公司 |
作为mnk抑制剂的杂环化合物
|
|
CA3071345A1
(en)
|
2017-07-28 |
2019-01-31 |
Yale University |
Anticancer drugs and methods of making and using same
|
|
AU2018325442B2
(en)
|
2017-08-31 |
2023-04-13 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of EGFR and/or HER2 and methods of use
|
|
AU2018325445A1
(en)
|
2017-08-31 |
2020-03-19 |
Abbvie Inc. |
Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
|
|
FI3677266T3
(fi)
|
2017-09-01 |
2024-03-22 |
Taiho Pharmaceutical Co Ltd |
Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori
|
|
CN109422755B
(zh)
|
2017-09-01 |
2023-07-04 |
上海医药集团股份有限公司 |
一种含氮杂环化合物、制备方法、中间体、组合物和应用
|
|
KR20240017986A
(ko)
|
2017-09-26 |
2024-02-08 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
암 치료를 위한 조성물 및 방법
|
|
CN111163775B
(zh)
|
2017-10-02 |
2023-07-11 |
勃林格殷格翰国际有限公司 |
作为cdk8/cdk19抑制剂的新型[1,6]萘啶化合物和衍生物
|
|
WO2019081486A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
4h-pyrrolo[3,2-c]pyridin-4-one derivatives
|
|
PL3728254T3
(pl)
|
2017-12-21 |
2023-06-12 |
Boehringer Ingelheim International Gmbh |
Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
|
|
CN108490184B
(zh)
|
2018-01-26 |
2021-01-08 |
中国科学院化学研究所 |
人pot1蛋白在白血病诊断中的用途
|
|
SG11202006945PA
(en)
|
2018-01-26 |
2020-08-28 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
TWI798334B
(zh)
|
2018-01-31 |
2023-04-11 |
大陸商迪哲(江蘇)醫藥股份有限公司 |
Erbb/btk抑制劑
|
|
JP7313364B2
(ja)
|
2018-02-21 |
2023-07-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体
|
|
JP2021104931A
(ja)
|
2018-02-22 |
2021-07-26 |
大日本住友製薬株式会社 |
含窒素複素環を有するジベンゾアゼピン誘導体
|
|
AU2019223168B2
(en)
|
2018-02-23 |
2024-09-12 |
The Regents Of The University Of Michigan |
EGFR dimer disruptors and use of the same
|
|
KR102526281B1
(ko)
|
2018-03-06 |
2023-04-27 |
베이징 사이텍-엠큐 파마슈티컬즈 리미티드 |
옥사지노-퀴나졸린 및 옥사지노-퀴놀린형 화합물, 이의 제조방법 및 용도
|
|
KR102782739B1
(ko)
|
2018-03-13 |
2025-03-20 |
보로노이 주식회사 |
2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
|
|
KR102901976B1
(ko)
|
2018-03-13 |
2025-12-24 |
보로노이 주식회사 |
2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
|
|
TWI811358B
(zh)
|
2018-05-08 |
2023-08-11 |
大陸商迪哲(江蘇)醫藥股份有限公司 |
ErbB受體抑制劑
|
|
WO2019214651A1
(zh)
|
2018-05-08 |
2019-11-14 |
南京明德新药研发有限公司 |
作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
|
|
WO2019222093A1
(en)
|
2018-05-14 |
2019-11-21 |
Ariad Pharmaceuticals, Inc. |
Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
WO2019226991A1
(en)
|
2018-05-25 |
2019-11-28 |
Essa Pharma, Inc. |
Androgen receptor modulators and methods for their use
|
|
WO2019228403A1
(en)
|
2018-05-29 |
2019-12-05 |
Fronthera U.S. Pharmaceuticals Llc |
Autotaxin inhibitors and uses thereof
|
|
JP2021527088A
(ja)
|
2018-06-14 |
2021-10-11 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Her2阻害剤としてのシアノキノリンアミド化合物及び使用方法
|
|
TW202012391A
(zh)
|
2018-07-04 |
2020-04-01 |
日商第一三共股份有限公司 |
二芳基醚型喹唑啉衍生物
|
|
EP3831823A4
(en)
|
2018-08-01 |
2022-04-27 |
Shanghai Ennovabio Pharmaceuticals Co., Ltd. |
PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION
|
|
US11945803B2
(en)
|
2018-08-07 |
2024-04-02 |
Tosk, Inc. |
Modulators of RAS GTPase
|
|
EP3833372A4
(en)
|
2018-08-10 |
2022-06-08 |
Blueprint Medicines Corporation |
TREATMENT OF EGFR MUTANT CANCER
|
|
HRP20240293T1
(hr)
|
2018-09-18 |
2024-05-24 |
F. Hoffmann - La Roche Ag |
Derivati kinazolina kao protutumorska sredstva
|
|
US20210353627A1
(en)
|
2018-09-21 |
2021-11-18 |
Spectrum Pharmaceuticals, Inc. |
Novel quinazoline egfr inhibitors
|
|
EP3856349A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
|
WO2020068867A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
|
CN111171020A
(zh)
|
2018-11-13 |
2020-05-19 |
上海轶诺药业有限公司 |
一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
|
|
CN115925705B
(zh)
|
2018-11-30 |
2024-12-31 |
江苏豪森药业集团有限公司 |
杂芳类衍生物调节剂、其制备方法和应用
|
|
CN113423403B
(zh)
|
2018-12-28 |
2025-02-18 |
大鹏药品工业株式会社 |
对l718和/或l792突变型治疗有抗性的egfr抑制剂
|
|
KR102809395B1
(ko)
|
2019-03-15 |
2025-05-16 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
암을 치료하기 위한 조성물 및 방법
|
|
JP7109013B2
(ja)
|
2019-03-19 |
2022-07-29 |
ボロノイ インコーポレイテッド |
ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
|
|
CN109912572B
(zh)
|
2019-03-29 |
2020-11-06 |
武汉德诺美生物医药股份有限公司 |
Egfr抑制剂及其医药用途
|
|
KR102915019B1
(ko)
|
2019-04-24 |
2026-01-21 |
바이엘 악티엔게젤샤프트 |
4H-피롤로[3,2-c]피리딘-4-온 화합물
|
|
US11365189B2
(en)
|
2019-04-25 |
2022-06-21 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of tyrosine kinase
|
|
CN112079830B
(zh)
|
2019-06-14 |
2023-12-22 |
上海翰森生物医药科技有限公司 |
含并环类衍生物抑制剂、其制备方法和应用
|
|
US12522615B2
(en)
|
2019-06-24 |
2026-01-13 |
Boehringer Ingelheim International Gmbh |
Macrocyclic compounds and derivatives as EGFR inhibitors
|
|
AU2020328598B2
(en)
|
2019-08-15 |
2026-07-02 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
CN112552302B
(zh)
|
2019-09-26 |
2022-05-13 |
深圳市塔吉瑞生物医药有限公司 |
取代的芳香稠合环衍生物及其组合物及用途
|
|
WO2021062327A1
(en)
|
2019-09-27 |
2021-04-01 |
Jubilant Biosys Limited |
Fused pyrimidine compounds, compositions and medicinal applications thereof
|
|
WO2021057796A1
(zh)
|
2019-09-29 |
2021-04-01 |
深圳市塔吉瑞生物医药有限公司 |
取代的稠合三环衍生物及其组合物及用途
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
WO2021127397A1
(en)
|
2019-12-19 |
2021-06-24 |
Black Diamond Therapeutics, Inc. |
Nitrogen heterocyclic compounds and methods of use
|
|
PH12022551574A1
(en)
|
2019-12-23 |
2024-02-26 |
Blueprint Medicines Corp |
Egfr inhibitors
|
|
US20230126204A1
(en)
|
2020-02-03 |
2023-04-27 |
Boehringer Ingelheim International Gmbh |
[1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
|
|
CN115052881B
(zh)
|
2020-02-03 |
2024-07-09 |
勃林格殷格翰国际有限公司 |
作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶
|
|
WO2021164697A1
(zh)
|
2020-02-18 |
2021-08-26 |
深圳市塔吉瑞生物医药有限公司 |
取代的酰胺衍生物及其组合物及用途
|
|
CA3175102A1
(en)
|
2020-03-13 |
2021-09-16 |
Suzhou Zanrong Pharma Ltd. |
Erbb receptor inhibitors as anti-tumor agents
|
|
WO2021185348A1
(zh)
|
2020-03-20 |
2021-09-23 |
深圳市塔吉瑞生物医药有限公司 |
取代的丙烯酰胺衍生物及其组合物及用途
|
|
CA3177214A1
(en)
|
2020-03-31 |
2021-10-07 |
Bayer Aktiengesellschaft |
3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
|
|
US11608343B2
(en)
|
2020-04-24 |
2023-03-21 |
Boehringer Ingelheim International Gmbh |
Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
|
|
WO2021226208A2
(en)
|
2020-05-05 |
2021-11-11 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|
|
KR102698413B1
(ko)
|
2020-05-05 |
2024-08-26 |
뉴베일런트, 아이엔씨. |
헤테로방향족 거대환식 에터 화학치료제
|
|
KR102860318B1
(ko)
|
2020-05-07 |
2025-09-16 |
삼성디스플레이 주식회사 |
유기 발광 소자 및 이를 포함한 전자 장치
|
|
WO2021231400A1
(en)
|
2020-05-12 |
2021-11-18 |
Accutar Biotechnology, Inc. |
Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
|
|
WO2021243596A1
(en)
|
2020-06-03 |
2021-12-09 |
InventisBio Co., Ltd. |
Aminopyrimidine compounds, preparation methods and uses thereof
|
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
|
CN113861195B
(zh)
|
2020-06-30 |
2022-11-18 |
上海和誉生物医药科技有限公司 |
一种多稠环egfr抑制剂及其制备方法和应用
|
|
CN113880804A
(zh)
|
2020-07-01 |
2022-01-04 |
微境生物医药科技(上海)有限公司 |
新型苯并咪唑化合物
|
|
US20230265098A1
(en)
|
2020-07-02 |
2023-08-24 |
Enliven Therapeutics, Inc. |
Alkyne quinazoline derivatives as inhibitors of erbb2
|
|
CN116096372B
(zh)
|
2020-07-09 |
2024-09-03 |
上海和誉生物医药科技有限公司 |
一种egfr抑制剂、其制备方法和在药学上的应用
|
|
CN113943288A
(zh)
|
2020-07-17 |
2022-01-18 |
微境生物医药科技(上海)有限公司 |
5,6-二氢吡嗪并[2,3-c]异喹啉化合物
|
|
KR102887500B1
(ko)
|
2020-08-10 |
2025-11-17 |
아비스코 테라퓨틱스 컴퍼니 리미티드 |
Egfr 억제제 및 이의 제조방법 및 응용
|
|
CN115836070B
(zh)
|
2020-08-10 |
2024-08-09 |
上海和誉生物医药科技有限公司 |
作为egfr抑制剂的稠环化合物及其制备方法和应用
|
|
CN115836064B
(zh)
|
2020-08-13 |
2024-08-27 |
上海和誉生物医药科技有限公司 |
具有egfr抑制活性的三嗪衍生物及其制备方法和应用
|
|
MX2023001997A
(es)
|
2020-08-17 |
2023-05-12 |
Betta Pharmaceuticals Co Ltd |
Compuestos biciclicos, composiciones y usos de los mismos.
|
|
WO2022042755A1
(zh)
|
2020-08-28 |
2022-03-03 |
华东理工大学 |
抑制突变型egfr的化合物及其应用
|
|
US20230372346A1
(en)
|
2020-09-08 |
2023-11-23 |
Cullinan Pearl Corp. |
Treatment regimens for exon-20 insertion mutant egfr cancers
|
|
KR20230069956A
(ko)
|
2020-09-14 |
2023-05-19 |
베링거 인겔하임 인터내셔날 게엠베하 |
이종 프라임 부스트 백신
|
|
US20230322753A1
(en)
|
2020-09-18 |
2023-10-12 |
Voronoi Inc. |
Heteroaryl derivative, method for preparation thereof, and pharmaceutical composition comprising same as active ingredient
|
|
MX2023003362A
(es)
|
2020-09-23 |
2023-05-30 |
Scorpion Therapeutics Inc |
Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
|
|
WO2022072645A2
(en)
|
2020-09-30 |
2022-04-07 |
Scorpion Therapeutics, Inc. |
Methods for treating cancer
|
|
WO2022072632A1
(en)
|
2020-09-30 |
2022-04-07 |
Scorpion Therapeutics, Inc. |
Bicyclic compounds for use in the treatment cancer
|
|
TW202229282A
(zh)
|
2020-09-30 |
2022-08-01 |
美商史考皮恩治療有限公司 |
治療癌症之方法
|
|
KR20230167009A
(ko)
|
2020-10-05 |
2023-12-07 |
다나-파버 캔서 인스티튜트 인크. |
Her2에 대한 강력하고 선택적인 억제제
|
|
WO2022076671A1
(en)
|
2020-10-08 |
2022-04-14 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers using quinazoline derivatives
|
|
BR112023006531A2
(pt)
|
2020-10-09 |
2023-10-03 |
Scorpion Therapeutics Inc |
Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
|
|
WO2022079175A1
(en)
|
2020-10-14 |
2022-04-21 |
Boehringer Ingelheim International Gmbh |
Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
|
|
WO2023077259A1
(en)
|
2021-11-02 |
2023-05-11 |
Enliven Therapeutics, Inc. |
Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
|
|
EP4237088A1
(en)
|
2020-10-30 |
2023-09-06 |
Blueprint Medicines Corporation |
Pyrimidine compounds, compositions, and medicinal applications thereof
|
|
EP4237418B1
(en)
|
2020-10-30 |
2026-02-11 |
Blueprint Medicines Corporation |
Pyrimidine compounds, compositions, and medicinal applications thereof
|
|
WO2022094271A1
(en)
|
2020-10-30 |
2022-05-05 |
Scorpion Therapeutics, Inc. |
Methods for treating cancer
|
|
JP7805363B2
(ja)
|
2020-11-02 |
2026-01-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
EGFR阻害薬としての置換1H-ピラゾロ[4,3-c]及び誘導体
|
|
WO2022098992A1
(en)
|
2020-11-05 |
2022-05-12 |
Scorpion Therapeutics, Inc. |
Use of macrocyclic compounds in methods of treating cancer
|
|
EP4244225B1
(en)
|
2020-11-11 |
2026-06-03 |
Bayer Aktiengesellschaft |
N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl}oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
|
|
WO2022105882A1
(zh)
|
2020-11-19 |
2022-05-27 |
上海翰森生物医药科技有限公司 |
一种含吲哚类衍生物的盐、晶型及其制备方法和应用
|
|
CN114539226B
(zh)
|
2020-11-19 |
2026-02-13 |
上海翰森生物医药科技有限公司 |
一种含吲哚类衍生物自由碱的晶型及其制备方法和应用
|
|
CN115803326B
(zh)
|
2020-11-23 |
2024-03-26 |
上海和誉生物医药科技有限公司 |
Egfr抑制剂及其制备方法与在药学上的应用
|
|
CN115867539B
(zh)
|
2020-12-02 |
2025-07-22 |
上海和誉生物医药科技有限公司 |
2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用
|
|
CN114621207B
(zh)
|
2020-12-11 |
2025-02-11 |
广东东阳光药业股份有限公司 |
一种作为甲状腺激素β受体激动剂的化合物及其用途
|
|
KR20220090443A
(ko)
|
2020-12-21 |
2022-06-29 |
주식회사 비투에스바이오 |
헤테로아릴 유도체 화합물 및 이의 용도
|
|
WO2022140769A1
(en)
|
2020-12-22 |
2022-06-30 |
Enliven Therapeutics, Inc. |
Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
|
|
UY39593A
(es)
|
2020-12-29 |
2022-07-29 |
Spectrum Pharmaceuticals Inc |
Tratamiento para tumores sólidos malignos
|
|
EP4273149A4
(en)
|
2020-12-29 |
2024-12-18 |
Voronoi Inc. |
HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF
|
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
|
CN114874189B
(zh)
|
2021-02-05 |
2023-09-29 |
深圳市塔吉瑞生物医药有限公司 |
取代的杂芳基衍生物及其组合物及用途
|
|
US20240398805A1
(en)
|
2021-02-05 |
2024-12-05 |
Accutar Biotechnology Inc. |
Quinazoline derived compounds as egfr inhibitors and their uses thereof
|
|
CN114907356A
(zh)
|
2021-02-10 |
2022-08-16 |
上海医药集团股份有限公司 |
一种含氮杂环化合物的晶型、其制备方法及应用
|
|
TW202300152A
(zh)
|
2021-03-10 |
2023-01-01 |
美商纜圖藥品公司 |
Egfr抑制劑
|
|
EP4306518A1
(en)
|
2021-03-11 |
2024-01-17 |
Oncobix Co., Ltd. |
Novel pyrimidine derivative showing inhibition effect on growth of cancer cells
|
|
WO2022194257A1
(zh)
|
2021-03-17 |
2022-09-22 |
江苏恒瑞医药股份有限公司 |
一种喜树碱衍生物的制备方法
|
|
WO2022197913A1
(en)
|
2021-03-18 |
2022-09-22 |
Scorpion Therapeutics, Inc. |
Bicyclic derivatives which can be used to treat cancer
|
|
JP7598180B2
(ja)
|
2021-03-19 |
2024-12-11 |
北京賽特明強医薬科技有限公司 |
キナゾリン系化合物、キナゾリン系化合物の組成物及び応用
|
|
US20240217977A1
(en)
|
2021-03-31 |
2024-07-04 |
Blueprint Medicines Corporation |
Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
|
|
WO2022206929A1
(zh)
|
2021-04-01 |
2022-10-06 |
上海医药集团股份有限公司 |
一种化合物在制备靶向ErbB2突变体的抑制药物中的应用
|
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
|
KR20220147021A
(ko)
|
2021-04-22 |
2022-11-02 |
보로노이 주식회사 |
헤테로아릴 유도체 화합물 및 이의 용도
|
|
US20240262815A1
(en)
|
2021-05-07 |
2024-08-08 |
Voronoi Inc. |
Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
|
|
WO2022237825A1
(zh)
|
2021-05-13 |
2022-11-17 |
上海和誉生物医药科技有限公司 |
具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用
|
|
CN115667251A
(zh)
|
2021-05-17 |
2023-01-31 |
株式会社沃若诺伊生物 |
杂芳基衍生物化合物、及其用途
|
|
AU2022282261A1
(en)
|
2021-05-24 |
2023-12-21 |
Taiho Pharmaceutical Co., Ltd. |
Treatment methods for subjects with cancer having an aberration in egfr and/or her2
|
|
AU2022284373A1
(en)
|
2021-06-04 |
2024-01-04 |
Boehringer Ingelheim International Gmbh |
Anti-sirp-alpha antibodies
|
|
WO2022266426A1
(en)
|
2021-06-17 |
2022-12-22 |
Black Diamond Therapeutics, Inc. |
6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
|
|
WO2022266458A1
(en)
|
2021-06-17 |
2022-12-22 |
Black Diamond Therapeutics, Inc. |
6-heterocycloalkyl-quinazoline derivatives and uses thereof
|
|
WO2022266425A1
(en)
|
2021-06-17 |
2022-12-22 |
Black Diamond Therapeutics, Inc. |
3-cyano-quinoline derivatives and uses thereof
|
|
WO2022266427A1
(en)
|
2021-06-17 |
2022-12-22 |
Black Diamond Therapeutics, Inc. |
4-(aryl-methyl-amino)-quinazoline derivatives and uses thereof
|
|
CN117836286A
(zh)
|
2021-06-22 |
2024-04-05 |
缆图药品公司 |
用于治疗癌症的杂环egfr抑制剂
|
|
WO2022271749A1
(en)
|
2021-06-22 |
2022-12-29 |
Blueprint Medicines Corporation |
Heterocyclic egfr inhibitors for use in the treatment of cancer
|
|
CN117940424A
(zh)
|
2021-06-22 |
2024-04-26 |
缆图药品公司 |
Egfr抑制剂
|
|
US20240382483A1
(en)
|
2021-06-22 |
2024-11-21 |
Blueprint Medicines Corporation |
Heterocyclic egfr inhibitors for use in the treatment of cancer
|
|
JP2024523506A
(ja)
|
2021-06-23 |
2024-06-28 |
ブループリント メディシンズ コーポレイション |
上皮成長因子受容体阻害剤の塩及び結晶形態
|
|
EP4359401A1
(en)
|
2021-06-23 |
2024-05-01 |
Blueprint Medicines Corporation |
Process for preparing egfr inhibitors
|
|
EP4359082A1
(en)
|
2021-06-26 |
2024-05-01 |
Array BioPharma Inc. |
Her2 mutation inhibitors
|
|
JP7839261B2
(ja)
|
2021-07-13 |
2026-04-01 |
コーリア リサーチ インスティテュート オブ ケミカル テクノロジー |
新規のピリミジン-2,4-ジアミン誘導体、その調製方法、ならびにそれを癌の予防または処置のための有効成分として含有する医薬組成物
|
|
KR20240044458A
(ko)
|
2021-08-05 |
2024-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Her2 억제제로서 사용하기 위한 트리시클릭 융합된 피리미딘 화합물
|
|
CA3228333A1
(en)
|
2021-08-05 |
2023-02-09 |
Korea Research Institute Of Chemical Technology |
Pyrimidine derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient
|
|
WO2023011505A1
(zh)
|
2021-08-06 |
2023-02-09 |
上海和誉生物医药科技有限公司 |
嘧啶或吡啶衍生物及其制备方法和在药学上的应用
|
|
WO2023028054A1
(en)
|
2021-08-24 |
2023-03-02 |
Arthrosi Therapeutics, Inc. |
Quinazoline compounds for treatment of disease
|
|
CA3231608A1
(en)
|
2021-10-01 |
2023-04-06 |
Amit M. Deshpande |
Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
|
|
TW202320768A
(zh)
|
2021-10-01 |
2023-06-01 |
美商努法倫特公司 |
雜芳族大環醚化合物之固體形式、醫藥組成物及製備
|
|
CR20240163A
(es)
|
2021-10-20 |
2024-06-12 |
Hoffmann La Roche |
Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas
|
|
WO2023081637A1
(en)
|
2021-11-02 |
2023-05-11 |
Enliven Therapeutics, Inc. |
Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
|
|
CR20240233A
(es)
|
2021-12-01 |
2024-07-17 |
Univ Vanderbilt |
Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
|
|
TW202340209A
(zh)
|
2021-12-01 |
2023-10-16 |
德商百靈佳殷格翰國際股份有限公司 |
用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
|
|
US20230227470A1
(en)
|
2021-12-01 |
2023-07-20 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
TW202337432A
(zh)
|
2021-12-01 |
2023-10-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
|
|
EP4476211A4
(en)
|
2022-02-09 |
2026-02-25 |
Enliven Inc |
ACYLIC HETEROCYCLIC QUINAZOLINE DERIVATIVES USED AS ERBB2 INHIBITORS
|
|
WO2023173083A1
(en)
|
2022-03-11 |
2023-09-14 |
Scorpion Therapeutics, Inc. |
Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
|
|
US20250206760A1
(en)
|
2022-03-28 |
2025-06-26 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
|
|
WO2023195773A1
(ko)
|
2022-04-05 |
2023-10-12 |
보로노이 주식회사 |
헤테로아릴 유도체 및 이의 용도
|